1-20 of 21
Ravindra Uppaluri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA

Eleni M. Rettig, Jonathan D. Schoenfeld, Julianna Miller, Bethany Sargent, Evan Carey, Danielle N. Margalit, Kartik Sehgal, Rosh K.V. Sethi, Ravindra Uppaluri, Roy B. Tishler, Laura A. Goguen, Donald J. Annino, Edward S. Sim, Vickie Y. Jo, Kristine S. Wong, Jeffrey P. Guenette, Robert I. Haddad, Glenn J. Hanna
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-3053
Published: 13 January 2025
View article titled, A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Open the PDF for A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA in another window
Includes: Supplementary data
Journal Articles

Abstract B024: Personalized tumor-informed circulating tumor (ct) DNA for advanced thyroid carcinoma

Kartik Sehgal, Theodora Pappa, Michael J. Dennis, Nicole J. Scarfo, Michelle S. Mullin, Tura Coombs, Roy B. Tishler, Danielle N. Margalit, Ravindra Uppaluri, Rosh K. Sethi, Jonathan D. Schoenfeld, Justine A. Barletta, Gerard M. Doherty, Erik K. Alexander, Laura A. Goguen, Eleni M. Rettig, Robert I. Haddad, Glenn J. Hanna
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B024.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B024
Published: 13 November 2024
View article titled, Abstract B024: Personalized tumor-informed circulating tumor (ct) DNA for advanced thyroid carcinoma
Journal Articles

Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma

Glenn J. Hanna, Michael J. Dennis, Nicole Scarfo, Michelle S. Mullin, Rosh K.V. Sethi, Kartik Sehgal, Donald J. Annino, Jr, Laura A. Goguen, Robert I. Haddad, Roy B. Tishler, Danielle N. Margalit, Ravindra Uppaluri, Jonathan D. Schoenfeld, Eleni M. Rettig
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3329–3336.
https://doi.org/10.1158/1078-0432.CCR-24-0590
Published: 01 August 2024
View article titled, Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Open the PDF for Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer

Shin Saito, Michihisa Kono, Hoang C.B. Nguyen, Ann Marie Egloff, Cameron Messier, Patrick Lizotte, Cloud Paweletz, Douglas Adkins, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1934–1944.
https://doi.org/10.1158/1078-0432.CCR-23-3477
Published: 01 May 2024
View article titled, Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Open the PDF for Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689

Arkadiy Klochikhin, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Brana, Christophe Le Tourneau, Ravindra Uppaluri, Nancy Y. Lee, Ezra E. W. Cohen, Rebecca Chernock, William Westra, Hong Liu, Burak Gumuscu, Kimberly Benjamin, Douglas Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-002.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-002
Published: 15 September 2023
View article titled, Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689
Journal Articles

Abstract PO-078: Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance

Michihisa Kono, Shin Saito, Geoff Ivison, Ayano Kondo, Aaron Mayer, Jonathan D. Schoenfeld, Ann Marie Egloff, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-078.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-078
Published: 15 September 2023
View article titled, Abstract PO-078: Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance
Journal Articles

Abstract PO-001: Circulating tumor-tissue modified HPV DNA testing in the clinical workup of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV Study

Sana Batool, Rosh K. V. Sethi, Annette Wang, Kirsten Dabekaussen, Ann Marie Egloff, Catherine Delvecchio Fitz, Ravindra Uppaluri, Jennifer Shin, Eleni M. Rettig
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-001.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-001
Published: 15 September 2023
View article titled, Abstract PO-001: Circulating tumor-tissue modified HPV DNA testing in the clinical workup of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV Study
Journal Articles

Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer

Aleksandar Obradovic, Diana Graves, Michael Korrer, Yu Wang, Sohini Roy, Abdullah Naveed, Yaomin Xu, Adam Luginbuhl, Joseph Curry, Michael Gibson, Kamran Idrees, Paula Hurley, Peng Jiang, X. Shirley Liu, Ravindra Uppaluri, Charles G. Drake, Andrea Califano, Young J. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2094–2109.
https://doi.org/10.1158/1078-0432.CCR-21-3570
Published: 13 May 2022
View article titled, Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Open the PDF for Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

Glenn J. Hanna, Anne O'Neill, Kee-Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Jr, Laura A. Goguen, Jason I. Kass, Eleni M. Rettig, Rosh K.V. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 468–478.
https://doi.org/10.1158/1078-0432.CCR-21-2635
Published: 01 February 2022
View article titled, Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

Tenny Mudianto, Katie M. Campbell, Jason Webb, Paul Zolkind, Zachary L. Skidmore, Rachel Riley, Erica K. Barnell, Ibrahim Ozgenc, Tusar Giri, Gavin P. Dunn, Douglas R. Adkins, Malachi Griffith, Ann Marie Egloff, Obi L. Griffith, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2326–2339.
https://doi.org/10.1158/1078-0432.CCR-19-4179
Published: 15 April 2021
View article titled, Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Open the PDF for Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 357.
https://doi.org/10.1158/1078-0432.CCR-20-4484
Published: 04 January 2021
View article titled, Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Open the PDF for Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial in another window
Journal Articles

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5140–5152.
https://doi.org/10.1158/1078-0432.CCR-20-1695
Published: 01 October 2020
View article titled, Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Open the PDF for Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Abstract A13: Neoadjuvant PD-1 mAb treatment induces postoperative immune memory responses against both immunodominant and immunorecessive antigens

Clint T. Allen, Jay Friedman, Paul Zolkind, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): A13.
https://doi.org/10.1158/1557-3265.AACRAHNS19-A13
Published: 15 June 2020
View article titled, Abstract A13: Neoadjuvant PD-1 mAb treatment induces postoperative immune memory responses against both immunodominant and immunorecessive antigens
Journal Articles

Abstract IA18: Interrogating anti-PD1 immunotherapy resistance mechanisms

Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): IA18.
https://doi.org/10.1158/1557-3265.AACRAHNS19-IA18
Published: 15 June 2020
View article titled, Abstract IA18: Interrogating anti-PD1 immunotherapy resistance mechanisms
Journal Articles

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells

Jay Friedman, Ellen C. Moore, Paul Zolkind, Yvette Robbins, Paul E. Clavijo, Lilian Sun, Sarah Greene, Megan V. Morisada, Wojciech K. Mydlarz, Nicole Schmitt, James W. Hodge, Hans Schreiber, Carter Van Waes, Ravindra Uppaluri, Clint Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 679–689.
https://doi.org/10.1158/1078-0432.CCR-19-2209
Published: 03 February 2020
View article titled, Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
Open the PDF for Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells in another window
Includes: Supplementary data
Journal Articles

Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer

Liye Zhou, Tenny Mudianto, Xiaojing Ma, Rachel Riley, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 290–300.
https://doi.org/10.1158/1078-0432.CCR-19-1351
Published: 03 January 2020
View article titled, Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer
Open the PDF for Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug

Man Ki Chung, Young Ho Jung, Joon Kyoo Lee, Soo Youn Cho, Oihana Murillo-Sauca, Ravindra Uppaluri, June Ho Shin, John B. Sunwoo
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (3): 674–683.
https://doi.org/10.1158/1078-0432.CCR-17-0866
Published: 31 January 2018
View article titled, CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug
Open the PDF for CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug in another window
Includes: Supplementary data
Journal Articles

Abstract IA21: Immunocompetent models of head and neck cancer

Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23_Supplement): IA21.
https://doi.org/10.1158/1557-3265.AACRAHNS17-IA21
Published: 30 November 2017
View article titled, Abstract IA21: Immunocompetent models of head and neck cancer
Journal Articles

Abstract PR01: Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma

Paul A. Zolkind, Katie M. Campbell, Tianxiang Lin, Zach Skidmore, Ashley Winkler, Erica Barnell, Tusar Giri, Douglas R. Adkins, Malachi Griffith, Gavin P. Dunn, Obi L. Griffith, Ravindra Uppaluri
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23_Supplement): PR01.
https://doi.org/10.1158/1557-3265.AACRAHNS17-PR01
Published: 30 November 2017
View article titled, Abstract PR01: Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma
Journal Articles

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

Ravindra Uppaluri, Ashley E. Winkler, Tianxiang Lin, Jonathan H. Law, Bruce H. Haughey, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Jason A. Diaz, Loren P. Michel, Tanya Wildes, Gavin P. Dunn, Paul Zolkind, Dorina Kallogjeri, Jay F. Piccirillo, Farrokh Dehdashti, Barry A. Siegel, Rebecca D. Chernock, James S. Lewis, Jr., Douglas R. Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (9): 2186–2194.
https://doi.org/10.1158/1078-0432.CCR-16-1469
Published: 30 April 2017
View article titled, Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial
Open the PDF for Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial in another window